Article
Medicine, General & Internal
Christopher C. H. Yip, L. Li, Thomas K. H. Lau, Vicky T. C. Chan, Carol C. H. Kwok, Joyce J. S. Suen, Frankie K. F. Mo, Winnie Yeo
Summary: This retrospective analysis compared the efficacy of olanzapine-based and NEPA-based regimens in controlling chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients receiving AC. The olanzapine group showed higher rates of no rescue therapy and no significant nausea during cycle 1 of AC. However, there were no differences in quality of life between the two groups. Multiple cycle assessment revealed higher rates of total control in the NEPA group in later cycles. These results do not support the superiority of either regimen for breast cancer patients receiving AC.
HONG KONG MEDICAL JOURNAL
(2023)
Article
Oncology
Luigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, Luigi Cavanna, Olga Martelli, Simona Carnio, Elena Collova, Federica Bertolini, Fausto Petrelli, Alessandra Cassano, Rita Chiari, Francesca Zanelli, Salvatore Pisconti, Isabella Vittimberga, Antonietta Letizia, Andrea Misino, Angela Gernone, Erminio Bonizzoni, Sara Pilotto, Sabino De Placido, Emilio Bria
Summary: This study investigated the impact of reducing dexamethasone (DEX) on the daily lives of cisplatin-treated patients. The results showed that reducing the dose of DEX when administered with NEPA did not have any adverse effects on the daily functioning of the patients.
Review
Oncology
Matti Aapro, Karin Jordan, Florian Scotte, Luigi Celio, Meinolf Karthaus, Eric Roeland
Summary: Chemotherapy-induced nausea and vomiting (CINV) is a common problem that affects patients' quality of life and the effectiveness of chemotherapy. NEPA, a fixed combination antiemetic, can improve adherence to guidelines and provide effective treatment for CINV.
CURRENT CANCER DRUG TARGETS
(2022)
Article
Oncology
Barbara Loteta, Annalisa Paviglianiti, Virginia Naso, Anna Ferreri, Tiziana Moscato, Giuseppe Console, Filippo Antonio Canale, Giuseppe Irrera, Marta Pugliese, Antonella Di Costanzo, Pasquale Fabio Provenzano, Viviana Loddo, Gaetana Porto, Giuseppa Cusumano, Letteria Russo, Nicola Meliambro, Valentina Romeo, Domenico Porcino, Salvatore Gallo, Tiziana Gangemi, Antonio Maria Rossetti, Massimo Martino
Summary: NEPA, without DEXA, proved to be a well-tolerated and effective antiemetic option for MM patients undergoing HDM followed by ASCT, with a 93% complete response rate within 120 hours.
SUPPORTIVE CARE IN CANCER
(2022)
Review
Pharmacology & Pharmacy
Matt Shirley
Summary: The drug combination Netupitant/palonosetron is a fixed-dose combination indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in adults. It has shown high complete response rates in clinical trials and is well-tolerated in both oral and IV formulations. This drug combination provides a simple and convenient option for patients receiving highly or moderately emetogenic chemotherapy.
Article
Pharmacology & Pharmacy
R. De Luca, C. Volpe, O. Mistretta, R. Paci, G. Ferrera, V Caputo, G. Rosati, G. Cicero
Summary: The study demonstrated the therapeutic benefits and safety of NEPA in managing and preventing chemotherapy-induced nausea and vomiting in both naive patients and those previously treated with 5HT3-RA and NK1-RA. The efficacy of NEPA was significant, while the use of antiemetic prophylaxis with 5HT3-RA or NK1-RA showed inadequate control of CINV events.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2021)
Article
Oncology
Rudolph M. Navari, Gary Binder, Erminio Bonizzoni, Rebecca Clark-Snow, Silvia Olivari, Eric J. Roeland
Summary: Oral NEPA was found to be more effective than a 3-day APR regimen in preventing delayed nausea and vomiting associated with cisplatin, based on the pooled efficacy data from three cisplatin registration trials.
Article
Oncology
Rui Chen, Hongyun Wang, Wen Zhong, Salvatore Chessari, Corinna Lanzarotti, Alberto Bernareggi, Pei Hu
Summary: The study evaluated the pharmacokinetic profile of netupitant and palonosetron in Chinese subjects after oral NEPA administration, showing similarities to previously reported data in Caucasians. Overall, NEPA was well tolerated with a safety profile consistent with pivotal trials in Caucasians.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2021)
Article
Oncology
Nicola Di Renzo, Maurizio Musso, Rosanna Scime, Alessandra Cupri, Tommasina Perrone, Clara De Risi, Domenico Pastore, Attilio Guarini, Andrea Mengarelli, Fabio Benedetti, Patrizio Mazza, Saveria Capria, Patrizia Chiusolo, Luca Cupelli, Vincenzo Federico, Valentina Bozzoli, Anna Rita Messa, Rosella Matera, Davide Seripa, Paolo Codega, Erminio Bonizzoni, Giorgina Specchia
Summary: NEPA administered with a simplified every-other-day schedule shows to be very effective in preventing CINV in patients at high risk of CINV undergoing chemomobilization of stem cells prior to ASCT.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Jonas Nilsson, Vittoria Piovesana, Marco Turini, Claudio Lezzi, Jennifer Eriksson, Matti Aapro
Summary: This study assessed the cost-effectiveness of NEPA in the Spanish market and compared it to other available treatments. The results showed that NEPA is more effective and less costly compared to other treatments.
SUPPORTIVE CARE IN CANCER
(2022)
Review
Oncology
Matti Aapro, Rudolph M. Navari, Eric Roeland, Li Zhang, Lee Schwartzberg
Summary: This study compared the efficacy of intravenous NEPA with oral NEPA and other NK(1)RA regimens, showing that intravenous NEPA has significant advantages in the treatment of nausea and vomiting, potentially offering a safer and more effective option.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Oncology
Luigi Celio, Rupert Bartsch, Matti Aapro
Summary: We retrospectively evaluated the efficacy of the NEPA plus single-dose DEX regimen in older patients treated with high-dose cisplatin and found that it provides effective antiemetic efficacy without adverse impact on daily functioning.
JOURNAL OF GERIATRIC ONCOLOGY
(2023)
Article
Oncology
Winnie Yeo, Leung Li, Thomas K. H. Lau, Kwai T. Lai, Vicky T. C. Chan, Kwan H. Wong, Christopher C. H. Yip, Elizabeth Pang, Maggie Cheung, Vivian Chan, Carol C. H. Kwok, Joyce J. S. Suen, Frankie K. F. Mo
Summary: Chemotherapy-induced nausea and vomiting (CINV) are common side effects of doxorubicin-cyclophosphamide (AC) chemotherapy. Different antiemetic regimens were compared in Chinese breast cancer patients undergoing AC treatment, with netupitant-containing triplets and the addition of olanzapine to aprepitant-containing triplets showing superior efficacy over doublets. Prolonged use of dexamethasone provided limited additional benefit.
CANCER BIOLOGY & MEDICINE
(2021)
Article
Oncology
Matti Aapro, Zoe Caprariu, Petio Chilingirov, Marika Chrapava, Razvan-Ovidiu Curca, Laurentia Gales, Alexandru C. Grigorescu, Joanna Huszno, Bara Karlinova, Renata Kellnerova, Miroslava Malejcikova, Mihai Marinca, Edgar Petru, Adam Pluzanski, Petra Pokorna, Zuzana Pribulova, Maryna Rubach, Gunther G. Steger, Petra Tesarova, Lubica Valekova, Nicolay Yordanov, Anna Walaszkowska-Czyz
Summary: This study evaluated the application of evidence-based antiemetic guidelines in the prevention of chemotherapy-induced nausea and vomiting. The study found inconsistencies between clinical practice and guideline-recommended treatment. Patients receiving guideline-consistent prophylaxis had significantly higher complete response rates and less impact on daily living compared to patients receiving guideline-inconsistent treatment.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Medicine, General & Internal
Yi Cheng, Zehua Wu, Lishuo Shi, Cailu Shen, Jianwei Zhang, Huabin Hu, Weiwei Li, Yue Cai, Xiaoyu Xie, Jiayu Ling, Qin Zheng, Yanhong Deng
Summary: This study evaluated the efficacy of aprepitant combined with palonosetron in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderate-emetogenic chemotherapy (MEC). The results showed that aprepitant was superior to dexamethasone in terms of achieving a complete response in preventing CINV, with fewer reported side effects in the aprepitant group.
Article
Health Care Sciences & Services
Paige E. Sheridan, Wendi G. LeBrett, Daniel P. Triplett, Eric J. Roeland, Andrew R. Bruggeman, Heidi N. Yeung, James D. Murphy
Summary: Palliative care has the capacity to substantially reduce healthcare expenditure among advanced cancer patients, with earlier consultation resulting in greater cost reductions.
AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE
(2021)
Review
Oncology
Matti Aapro, Rudolph M. Navari, Eric Roeland, Li Zhang, Lee Schwartzberg
Summary: This study compared the efficacy of intravenous NEPA with oral NEPA and other NK(1)RA regimens, showing that intravenous NEPA has significant advantages in the treatment of nausea and vomiting, potentially offering a safer and more effective option.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Meeting Abstract
Oncology
Daniel W. Kim, Grace Lee, Theodore S. Hong, Li Guichao, Eric Roeland, Florence Keane, Christine Elissa Eyler, Lorraine C. Drapek, David P. Ryan, Jill N. Allen, David L. Berger, Aparna Raj Parikh, John Mullen, Samuel J. Klempner, Jeffrey William Clark, Jennifer Y. Wo
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Emma Uchida, Matthew M. Lei, Eric Roeland, Uvette Lou
Summary: This study evaluated the efficacy of antiemetic prophylaxis in lymphoma patients receiving a multiday doxorubicin-cyclophosphamide containing regimen, showing a suboptimal complete response rate of 32%. This highlights the importance of improving awareness and implementation of evidence-based guidelines for managing chemotherapy-induced nausea and vomiting in this patient population.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2022)
Article
Health Care Sciences & Services
Erin R. Currie, Emily E. Johnston, Marie Bakitas, Eric Roeland, Lisa C. Lindley, Stephanie Gilbertson-White, Jennifer Mack
Summary: The study revealed that there are many unmet needs in the quality of end-of-life care for adolescents and young adults with cancer, especially in terms of communication and emotional support.
JOURNAL OF PALLIATIVE CARE
(2022)
Article
Oncology
Daniel W. Kim, Grace Lee, Theodore S. Hong, Guichao Li, Nora K. Horick, Eric Roeland, Florence K. Keane, Christine Eyler, Lorraine C. Drapek, David P. Ryan, Jill N. Allen, David Berger, Aparna R. Parikh, John T. Mullen, Sam J. Klempner, Jeffrey W. Clark, Jennifer Y. Wo
Summary: This study compared the survival outcomes between neoadjuvant and postoperative chemoradiotherapy for patients with gastric and gastroesophageal junction cancer, and found that neoadjuvant CRT was associated with longer overall survival, higher rate of R0 resection, and lower treatment-related toxicity compared to postoperative CRT.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Editorial Material
Oncology
Stephen M. Schleicher, Basit Chaudhry, Natalie R. Dickson, Emeline Aviki, Edward Arrowsmith, Ravi B. Parikh, Andrew T. Yue, Nora Connor, Lee Schwartzberg, Aaron J. Lyss
JCO ONCOLOGY PRACTICE
(2021)
Review
Oncology
Bolivar Arboleda, Rupert Bartsch, Evandro de Azambuja, Erika Hamilton, Nadia Harbeck, Jennifer Klemp, Michael Knauer, Sherko Kuemmel, Reshma Mahtani, Lee Schwartzberg, Cynthia Villarreal-Garza, Antonio Wolff
Summary: This article summarizes the key results of an expert panel discussion on optimizing ovarian function suppression for premenopausal women with HR+, HER2- early breast cancer. The panel suggests that combining chemotherapy with ovarian function suppression may result in better treatment outcomes and avoid adverse effects associated with adjuvant chemotherapy.
Article
Oncology
Xin Hu, Cameron M. Kaplan, Michelle Y. Martin, Mark S. Walker, Edward Stepanski, Lee S. Schwartzberg, Gregory A. Vidal, Ilana Graetz
Summary: This study compared symptom changes before and during chemotherapy in breast cancer patients and found that black women experienced significant increases in physical and psychological symptom burden during chemotherapy, indicating inadequate symptom management among black women.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2023)
Article
Oncology
Ilana Graetz, Xin Hu, Andrea N. Curry, Andrew Robles, Gregory A. Vidal, Lee S. Schwartzberg
Summary: This study evaluated the impact of a self-management app on quality of life and healthcare utilization during cancer treatment. The results showed fewer medical visits and visits to mental health professionals in the intervention group using the app. However, some participants did not use the app due to personal preferences and usability challenges.
Article
Oncology
Lee Schwartzberg, Davey Daniel, Daniel Vaena, Dennis Slater, Harry Staszewski, Bruno Fang, Lasika Seneviratne, Elaine Yu, Richard Price, Tania Szado, Craig S. Meyer, Anuj Shah, Esprit Ma
Summary: This article examines the biomarker testing rates of lung and colon cancer patients in a large community oncology network in the USA. The study finds that the testing rates are high in the network, but lower for next-generation sequencing (NGS) due to operational challenges and insufficient tissue collection.
Article
Oncology
Lee S. Schwartzberg, Lesli A. Kiedrowski
Summary: This case report demonstrates clinical response to olaparib as a later-line therapy for HR+, HER2- mBC with a somatic BRCA2 mutation.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Meeting Abstract
Oncology
Rudolph M. Navari, Gary Binder, Eric J. Roeland, Alexander Molassiotis, Kathryn J. Ruddy, Thomas W. LeBlanc, Dwight D. Kloth, Silvia Sebastiani, Marco Turini, Luke M. Schmerold, Xing Liu, Lee Schwartzberg
Meeting Abstract
Oncology
Rudolph M. Navari, Gary Binder, Alexander Molassiotis, Eric Roeland, Kathryn J. Ruddy, Thomas W. LeBlanc, Dwight D. Kloth, Silvia Sebastiani, Lina Y. Dimberg, Luke M. Schmerold, Xing Liu, Lee Schwartzberg
Article
Oncology
Emily E. van Seventer, Madeleine G. Fish, Kathryn Fosbenner, Katie Kanter, Amirkasra Mojtahed, Jill N. Allen, Lawrence Blaszkowsky, Jeffrey W. Clark, Jon Dubois, Joseph W. Franses, Bruce J. Giantonio, Lipika Goyal, Samuel J. Klempner, Eric J. Roeland, David P. Ryan, Colin D. Weekes, Therese Mulvey, Areej El-Jawahri, Nora Horick, Ryan B. Corcoran, Aparna R. Parikh, Ryan D. Nipp
Summary: This study found that baseline patient-reported outcomes (PROs) are associated with treatment response, healthcare utilization, and survival in patients with advanced gastrointestinal cancer. Specifically, physical symptoms and functional quality of life were correlated with disease progression and survival.